Mainz Biomed (MYNZ) Competitors $2.08 +0.02 (+0.97%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$2.04 -0.04 (-1.73%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. PASG, DARE, CVKD, ABVC, EGRX, GBIO, GDTC, IPA, CYCC, and TENXShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Passage Bio (PASG), Daré Bioscience (DARE), Cadrenal Therapeutics (CVKD), ABVC BioPharma (ABVC), Eagle Pharmaceuticals (EGRX), Generation Bio (GBIO), CytoMed Therapeutics (GDTC), ImmunoPrecise Antibodies (IPA), Cyclacel Pharmaceuticals (CYCC), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Passage Bio Daré Bioscience Cadrenal Therapeutics ABVC BioPharma Eagle Pharmaceuticals Generation Bio CytoMed Therapeutics ImmunoPrecise Antibodies Cyclacel Pharmaceuticals Tenax Therapeutics Mainz Biomed (NASDAQ:MYNZ) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Which has more risk and volatility, MYNZ or PASG? Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Do analysts rate MYNZ or PASG? Mainz Biomed presently has a consensus price target of $14.00, suggesting a potential upside of 573.08%. Passage Bio has a consensus price target of $7.50, suggesting a potential upside of 1,464.13%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts plainly believe Passage Bio is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor MYNZ or PASG? Passage Bio received 39 more outperform votes than Mainz Biomed when rated by MarketBeat users. However, 73.68% of users gave Mainz Biomed an outperform vote while only 68.83% of users gave Passage Bio an outperform vote. CompanyUnderperformOutperformMainz BiomedOutperform Votes1473.68% Underperform Votes526.32% Passage BioOutperform Votes5368.83% Underperform Votes2431.17% Which has better valuation & earnings, MYNZ or PASG? Mainz Biomed has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$893.99K8.00-$26.30M-$65.60-0.03Passage BioN/AN/A-$102.06M-$1.02-0.47 Does the media refer more to MYNZ or PASG? In the previous week, Mainz Biomed had 4 more articles in the media than Passage Bio. MarketBeat recorded 5 mentions for Mainz Biomed and 1 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.87 beat Mainz Biomed's score of -0.32 indicating that Passage Bio is being referred to more favorably in the news media. Company Overall Sentiment Mainz Biomed Neutral Passage Bio Very Positive Is MYNZ or PASG more profitable? Mainz Biomed's return on equity of 0.00% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A Passage Bio N/A -72.53%-52.10% Do institutionals and insiders hold more shares of MYNZ or PASG? 53.5% of Passage Bio shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Comparatively, 5.0% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryMainz Biomed and Passage Bio tied by winning 8 of the 16 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.16M$6.78B$5.55B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-0.038.7927.2220.17Price / Sales8.00263.83423.71161.98Price / CashN/A65.8538.2534.64Price / Book0.196.677.134.72Net Income-$26.30M$143.49M$3.23B$247.80M7 Day Performance1.96%5.15%3.78%2.75%1 Month Performance-15.45%15.42%13.34%9.70%1 Year Performance-92.12%6.02%32.21%14.51% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.7978 of 5 stars$2.08+1.0%$14.00+573.1%-93.1%$7.16M$893,991.00-0.0330News CoveragePositive NewsGap DownPASGPassage Bio3.0527 of 5 stars$0.44+0.6%$7.50+1,608.4%-56.0%$27.28MN/A-0.38130Positive NewsDAREDaré Bioscience1.6863 of 5 stars$3.01+1.3%$12.00+298.7%-44.6%$26.64M$25,909.00-5.1030Analyst RevisionCVKDCadrenal Therapeutics2.9303 of 5 stars$13.47+1.1%$32.00+137.5%N/A$26.50MN/A-2.024Positive NewsABVCABVC BioPharma0.6126 of 5 stars$1.56+13.5%N/A+107.8%$26.41M$508,384.00-1.8130Positive NewsEGRXEagle PharmaceuticalsN/A$2.00+5.3%N/A-41.0%$25.97M$257.55M0.00100Gap DownGBIOGeneration Bio3.6231 of 5 stars$0.39+2.1%$7.33+1,799.8%-85.8%$25.88M$24.56M-0.18150Positive NewsGap UpGDTCCytoMed Therapeutics1.9747 of 5 stars$2.37+1.9%$5.00+111.4%+3.8%$25.87M$69,501.000.00N/APositive NewsIPAImmunoPrecise Antibodies3.1619 of 5 stars$0.57-0.9%$4.00+608.0%-37.1%$25.86M$24.00M-0.7280Gap UpCYCCCyclacel Pharmaceuticals1.3883 of 5 stars$1.65+1.2%N/A-99.1%$25.41M$14,000.00-0.1814Positive NewsTENXTenax Therapeutics1.5817 of 5 stars$6.09+0.6%$17.50+187.6%+68.5%$25.24MN/A-2.459Positive News Related Companies and Tools Related Companies Passage Bio Alternatives Daré Bioscience Alternatives Cadrenal Therapeutics Alternatives ABVC BioPharma Alternatives Eagle Pharmaceuticals Alternatives Generation Bio Alternatives CytoMed Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Cyclacel Pharmaceuticals Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
